Cytek Biosciences (CTKB) announced that its Board of Directors has approved a stock repurchase program for up to an additional aggregate of $50 million of its common stock, subject to compliance with applicable law, to succeed the expiration of the existing $50 million repurchase program on December 31, 2024. The new repurchase program is authorized to commence on January 1, 2025 and remain in effect until December 31, 2025 unless extended or shortened by the Board of Directors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTKB:
- Cytek Biosciences price target raised to $8.50 from $8 at Piper Sandler
- Cytek Biosciences introduces ESP Detection Option for Cytek Aurora
- Trump Media, broader market surge after Trump wins election: Morning Buzz
- Cytek Biosciences’ Q3 2024 Financial Highlights
- Cytek Biosciences reports Q3 EPS 1c, consensus (2c)